AU6430599A - Enzymatic synthesis of ssdna - Google Patents
Enzymatic synthesis of ssdna Download PDFInfo
- Publication number
- AU6430599A AU6430599A AU64305/99A AU6430599A AU6430599A AU 6430599 A AU6430599 A AU 6430599A AU 64305/99 A AU64305/99 A AU 64305/99A AU 6430599 A AU6430599 A AU 6430599A AU 6430599 A AU6430599 A AU 6430599A
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- vector
- reverse transcriptase
- interest
- genetic elements
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108020004414 DNA Proteins 0.000 title claims description 67
- 102000053602 DNA Human genes 0.000 title description 43
- 230000015572 biosynthetic process Effects 0.000 title description 8
- 238000003786 synthesis reaction Methods 0.000 title description 7
- 230000002255 enzymatic effect Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 117
- 239000013598 vector Substances 0.000 claims description 100
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 90
- 150000007523 nucleic acids Chemical class 0.000 claims description 83
- 230000002068 genetic effect Effects 0.000 claims description 71
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 230000027455 binding Effects 0.000 claims description 61
- 230000002401 inhibitory effect Effects 0.000 claims description 56
- 239000013612 plasmid Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 48
- 108020004999 messenger RNA Proteins 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 40
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 239000003623 enhancer Substances 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 18
- 230000001575 pathological effect Effects 0.000 claims description 18
- 108091023037 Aptamer Proteins 0.000 claims description 14
- 108020004566 Transfer RNA Proteins 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 102100031780 Endonuclease Human genes 0.000 claims description 9
- 108091027305 Heteroduplex Proteins 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- 108010076039 Polyproteins Proteins 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 description 35
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 108090001007 Interleukin-8 Proteins 0.000 description 25
- 102000004890 Interleukin-8 Human genes 0.000 description 23
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 241000701022 Cytomegalovirus Species 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102100023471 E-selectin Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000010804 cDNA synthesis Methods 0.000 description 14
- 108020004635 Complementary DNA Proteins 0.000 description 13
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 13
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 108010024212 E-Selectin Proteins 0.000 description 11
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 11
- 208000030507 AIDS Diseases 0.000 description 10
- 208000007766 Kaposi sarcoma Diseases 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 7
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- 102400000967 Bradykinin Human genes 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000015689 E-Selectin Human genes 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- 241000701027 Human herpesvirus 6 Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 206010061494 Rhinovirus infection Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- 108010038415 interleukin-8 receptors Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108700021654 myb Genes Proteins 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000724256 Brome mosaic virus Species 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710082498 C-X-C chemokine receptor type 2 Proteins 0.000 description 1
- 108091028690 C-myc mRNA Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 241001125831 Istiophoridae Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010054076 Oncogene Proteins v-myb Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 101710187995 Transcriptional activator Myb Proteins 0.000 description 1
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101150050388 UL20 gene Proteins 0.000 description 1
- 101150003230 UL27 gene Proteins 0.000 description 1
- 101150008036 UL29 gene Proteins 0.000 description 1
- 101150068034 UL30 gene Proteins 0.000 description 1
- 101150099321 UL42 gene Proteins 0.000 description 1
- 101150011902 UL52 gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- RYNBQQWODYCGRR-UHFFFAOYSA-N ethyl 5-(4-chlorophenyl)-2-methyl-1-phenylpyrrole-3-carboxylate Chemical compound C=1C=CC=CC=1N1C(C)=C(C(=O)OCC)C=C1C1=CC=C(Cl)C=C1 RYNBQQWODYCGRR-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150029683 gB gene Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16979398A | 1998-10-09 | 1998-10-09 | |
| US09169793 | 1998-10-09 | ||
| US39778399A | 1999-09-16 | 1999-09-16 | |
| US09397783 | 1999-09-16 | ||
| PCT/US1999/023933 WO2000022113A1 (fr) | 1998-10-09 | 1999-10-12 | Synthese enzymatique d'adn simple brin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6430599A true AU6430599A (en) | 2000-05-01 |
Family
ID=26865381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU64305/99A Abandoned AU6430599A (en) | 1998-10-09 | 1999-10-12 | Enzymatic synthesis of ssdna |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1117776A1 (fr) |
| JP (1) | JP2002527061A (fr) |
| KR (1) | KR20010099682A (fr) |
| AU (1) | AU6430599A (fr) |
| BR (1) | BR9914772A (fr) |
| CA (1) | CA2346155A1 (fr) |
| IL (1) | IL142490A0 (fr) |
| MX (1) | MXPA01003642A (fr) |
| WO (1) | WO2000022113A1 (fr) |
Families Citing this family (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7419964B2 (en) * | 1999-09-16 | 2008-09-02 | Cytogenix, Inc. | Treatment of HSV-related pathologies using ssDNA |
| CN1276083C (zh) * | 1999-10-04 | 2006-09-20 | 西托吉尼克斯公司 | 用体内产生的ssDNA改变基因表达 |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| CN1620503A (zh) * | 2001-12-14 | 2005-05-25 | 耶鲁大学 | 细胞内制备单链dna |
| EP2365077B1 (fr) | 2004-03-12 | 2013-05-08 | Alnylam Pharmaceuticals, Inc. | Agents ARNi ciblant le facteur de croissance de l'endothélium vasculaire (VEGF) |
| CA2582814A1 (fr) * | 2004-09-28 | 2006-04-06 | Cytogenix, Inc. | Oligonucleotides antimicrobiens monocatenaires et leurs utilisations |
| CA2626690A1 (fr) | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions et procedes destines a inhiber l'expression de la mutation du gene du facteur v leiden |
| US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
| JP5704741B2 (ja) | 2006-03-31 | 2015-04-22 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇ５遺伝子発現の抑制のための組成物および方法 |
| US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
| US7605251B2 (en) | 2006-05-11 | 2009-10-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| CN101489566B (zh) | 2006-05-19 | 2012-04-18 | 阿尔尼拉姆医药品有限公司 | Aha基因的RNAi调控及其治疗性应用 |
| AU2007253677B2 (en) | 2006-05-22 | 2011-02-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
| EP2069380B1 (fr) | 2006-09-18 | 2014-11-12 | Alnylam Pharmaceuticals Inc. | MODULATION PAR L'ARNi DU GÈNE SCAP ET UTILISATIONS THÉRAPEUTIQUES |
| AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| EP2319926B1 (fr) | 2007-07-05 | 2016-08-31 | Arrowhead Research Corporation | ARNDB pour le traitement de l'infection virale |
| JP5530933B2 (ja) | 2007-12-10 | 2014-06-25 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法 |
| WO2009111658A2 (fr) | 2008-03-05 | 2009-09-11 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés pour inhiber l’expression des gènes eg5 et vegf |
| EP2331690B1 (fr) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant |
| US8546554B2 (en) | 2008-09-25 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene |
| KR102578331B1 (ko) | 2008-10-20 | 2023-09-15 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴의 발현을 억제하기 위한 조성물 및 방법 |
| NZ593618A (en) | 2008-12-10 | 2013-02-22 | Alnylam Pharmaceuticals Inc | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| BRPI1008109A2 (pt) | 2009-02-03 | 2015-08-25 | Hoffmann La Roche | "composições e métodos para a inibição de expressão de genes de ptp1b". |
| WO2010099341A1 (fr) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Composition et procédés d'inhibition de l'expression du gène mig-12 |
| CN102421900B (zh) | 2009-03-12 | 2015-07-22 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法 |
| BRPI1010689A2 (pt) | 2009-06-15 | 2016-03-15 | Alnylam Pharmaceuticals Inc | "dsrna formulado por lipídios direcionados para o gene pcsk9" |
| WO2010147992A1 (fr) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Procédés pour augmenter l'efficacité d'arnsi dans une formulation lipidique |
| WO2011054939A2 (fr) | 2009-11-09 | 2011-05-12 | F. Hoffmann-La Roche Ag | Compositions et procédés pour inhiber l'expression de gènes kif10 |
| US20110152349A1 (en) | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
| US20110196016A1 (en) | 2010-02-05 | 2011-08-11 | Anke Geick | Compositions and Methods for Inhibiting Expression of IKK2 Genes |
| EP3329924B1 (fr) | 2010-03-29 | 2021-05-05 | Alnylam Pharmaceuticals, Inc. | Thérapie d'arndb pour amylose oculaire associée à la transthyrétine (ttr) |
| AU2011237630B2 (en) | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| WO2011153323A2 (fr) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes pour traiter une fibrose hépatique |
| EP3434772A3 (fr) | 2010-10-18 | 2019-03-20 | Arrowhead Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression de gènes rrm2 |
| US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| WO2012078967A2 (fr) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo) |
| EP3674409A1 (fr) | 2011-03-29 | 2020-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés permettant d'inhiber l'expression du gène tmprss6 |
| EP3564393A1 (fr) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Analyses et procédés pour déterminer l'activité d'un agent thérapeutique chez un sujet |
| MX345095B (es) | 2011-06-21 | 2017-01-17 | Alnylam Pharmaceuticals Inc | Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso. |
| KR20230084331A (ko) | 2011-06-21 | 2023-06-12 | 알닐람 파마슈티칼스 인코포레이티드 | 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법 |
| WO2012177949A2 (fr) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc) |
| WO2012177921A2 (fr) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc | Compositions et procédés d'inhibition de l'expression du peptide antimicrobien hepcidine (hamp) ou du gène lié à hamp |
| EP4134433A1 (fr) | 2011-06-23 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Arnsi de serpina 1 : compositions de matière et procédés de traitement |
| KR102554783B1 (ko) | 2011-06-30 | 2023-07-11 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| US20140328811A1 (en) | 2011-08-01 | 2014-11-06 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EP3336187A1 (fr) | 2012-12-05 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni pcsk9 et leurs procédés d'utilisation |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2014160418A2 (fr) | 2013-03-13 | 2014-10-02 | GeneWeave Biosciences, Inc. | Particules de transduction non réplicative et systèmes rapporteurs à base de particules de transduction |
| LT2970974T (lt) | 2013-03-14 | 2017-12-11 | Alnylam Pharmaceuticals, Inc. | Komplemento komponento c5 irnr kompozicijos ir jų panaudojimas |
| EP2978446B1 (fr) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anticorps anti-cd33 pour le traitement de la maladie d'alzheimer |
| WO2014182661A2 (fr) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages et méthodes pour administrer des molécules d'acides nucléiques à formulation lipidique |
| EA038792B1 (ru) | 2013-05-22 | 2021-10-20 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| TWI727917B (zh) | 2013-05-22 | 2021-05-21 | 美商阿尼拉製藥公司 | ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法 |
| US10077444B2 (en) | 2013-10-02 | 2018-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
| EP3052627B1 (fr) | 2013-10-04 | 2018-08-22 | Novartis AG | Formats inédits pour composés organiques utilisables en interférence arn |
| EP3052464B1 (fr) | 2013-10-04 | 2020-04-15 | Novartis AG | 3'end caps pour des agents arni utilisés dans l'interférence d'arn |
| BR112016007226B1 (pt) | 2013-10-04 | 2021-12-07 | Alnylam Pharmaceuticals, Inc. | Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica e seus usos |
| EP3052107B1 (fr) | 2013-10-04 | 2018-05-02 | Novartis AG | Composés organiques destinés au traitement du virus de l'hépatite b |
| IL294470B1 (en) | 2013-12-12 | 2024-08-01 | Alnylam Pharmaceuticals Inc | Complementary component iRNA compositions and methods for using them |
| CN106103718B (zh) | 2014-02-11 | 2021-04-02 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
| WO2015175510A1 (fr) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Méthodes et compositions pour le traitement d'un trouble associé à serpinc1 |
| EP3146049B1 (fr) | 2014-05-22 | 2020-02-26 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni produisant un effet sur l'angiotensinogène (agt) et leurs procédés d'utilisation |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| WO2016081444A1 (fr) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni d'apolipoprotéine c3 (apoc3) et procédés d'utilisation de ces compositions |
| AU2016219263B2 (en) | 2015-02-13 | 2022-12-01 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof |
| WO2016168286A1 (fr) | 2015-04-13 | 2016-10-20 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni faisant intervenir la protéine 3 de type angiopoïétine (angptl3) et leurs procédés d'utilisation |
| WO2016179342A2 (fr) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de facteur xii (facteur hageman) (f12), de la kallicréine b plasmatique (facteur fletcher) 1 (klkb1) et de kininogène 1 (kng1) et procédés d'utilisation associés |
| EP4365291A3 (fr) | 2015-06-12 | 2024-08-14 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni c5 de composant du complément et leurs procédés d'utilisation |
| WO2016209862A1 (fr) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Compositions d'arndb contre un gène de glucokinase (gck) et leurs procédés d'utilisation |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| CN108271387B (zh) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| KR20180051550A (ko) | 2015-09-02 | 2018-05-16 | 알닐람 파마슈티칼스 인코포레이티드 | 프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법 |
| TW201718857A (zh) | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | 用於抑制alas1基因表現之組合物及方法 |
| JP6985283B2 (ja) | 2015-12-07 | 2021-12-22 | ジェンザイム・コーポレーション | Ｓｅｒｐｉｎｃ１関連障害を処置するための方法および組成物 |
| WO2017100542A1 (fr) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni chaperon (scap) de la protéine srebp (sterol regulatory element binding protein), et procédés d'utilisation associés |
| EP3416976A2 (fr) | 2016-02-16 | 2018-12-26 | Yale University | Compositions permettant d'améliorer l'édition ciblée de gènes et leurs procédés d'utilisation |
| MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
| EP3469083A1 (fr) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn) |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| US20190350962A1 (en) | 2016-12-16 | 2019-11-21 | Alnylam Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS |
| BR112019021852A2 (pt) | 2017-04-18 | 2020-06-02 | Alnylam Pharmaceuticals, Inc. | Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento |
| JP7277432B2 (ja) | 2017-07-13 | 2023-05-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法 |
| US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| WO2019099610A1 (fr) | 2017-11-16 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de kisspeptine 1 (kiss1) et leurs méthodes d'utilisation |
| EP3714054A1 (fr) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation |
| MX2020006012A (es) | 2017-12-18 | 2020-09-14 | Alnylam Pharmaceuticals Inc | Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas. |
| US11008602B2 (en) | 2017-12-20 | 2021-05-18 | Roche Molecular Systems, Inc. | Non-replicative transduction particles and transduction particle-based reporter systems |
| CN112313335B (zh) | 2018-05-14 | 2024-07-09 | 阿尔尼拉姆医药品有限公司 | 血管紧张素原(AGT)iRNA组合物及其使用方法 |
| US11987792B2 (en) | 2018-08-16 | 2024-05-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
| AU2019344776A1 (en) | 2018-09-18 | 2021-01-21 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| WO2020104649A2 (fr) | 2018-11-23 | 2020-05-28 | Sanofi | Nouvelles compositions d'arn et méthodes d'inhibition d'angptl8 |
| KR20210109537A (ko) | 2018-12-27 | 2021-09-06 | 에프. 호프만-라 로슈 아게 | 아시네토박터 바우마니의 검출을 위한 비-복제 형질 도입 입자 및 형질 도입 입자 기반의 리포터 시스템 |
| US11572595B2 (en) | 2018-12-31 | 2023-02-07 | Roche Molecular Systems, Inc. | Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems |
| EP4007811A2 (fr) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de carboxypeptidase b2 (cpb2) et leurs procédés d'utilisation |
| WO2021022109A1 (fr) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la famille des serpines 2 (serpinf2) et leurs procedes d'utilisation |
| WO2021030522A1 (fr) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni à sous-unité de protéine ribosomale 25 (rps25) et leurs procédés d'utilisation |
| US20220290156A1 (en) | 2019-08-27 | 2022-09-15 | Sanofi | Compositions and methods for inhibiting pcsk9 |
| CN114616331B (zh) | 2019-09-03 | 2024-10-22 | 阿尔尼拉姆医药品有限公司 | 抑制lect2基因表达的组合物和方法 |
| WO2021061707A1 (fr) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions et procédés pour moduler l'expression génique de l'apolipoprotéine b (apob) |
| AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| EP4038189A1 (fr) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes pour le silençage de l'expression génique de l'ugt1a1 |
| US20240050529A1 (en) | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| US20240141358A1 (en) | 2019-10-18 | 2024-05-02 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
| MX2022004726A (es) | 2019-10-22 | 2022-05-13 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) de componente c3 de complemento y metodos de uso de las mismas. |
| EP4051796A1 (fr) | 2019-11-01 | 2022-09-07 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes pour rendre silencieuse l'expression du gène de fusion dnajb1-prkaca |
| AR120341A1 (es) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
| IL292865A (en) | 2019-11-13 | 2022-07-01 | Alnylam Pharmaceuticals Inc | Methods and preparations for the treatment of angiotensinogen-related disorder - (agt) |
| WO2021102373A1 (fr) | 2019-11-22 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent arni d'ataxine 3 (atxn3) et leurs procédés d'utilisation |
| CN115151641A (zh) | 2019-12-13 | 2022-10-04 | 阿尔尼拉姆医药品有限公司 | 人类染色体9开放阅读框72(C9ORF72)iRNA剂组合物及其使用方法 |
| WO2021126734A1 (fr) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du gène codant pour la protéine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs méthodes d'utilisation |
| WO2021136752A1 (fr) | 2019-12-31 | 2021-07-08 | F. Hoffmann-La Roche Ag | Criblage par pcr quantitative de prophages inductibles à partir d'isolats bactériens |
| EP4093426A1 (fr) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulation de vaisseaux lymphatiques dans une maladie neurologique |
| WO2021154941A1 (fr) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla) |
| JP2023514190A (ja) | 2020-02-10 | 2023-04-05 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｖｅｇｆ－ａ発現をサイレンシングするための組成物および方法 |
| EP4107265A1 (fr) | 2020-02-18 | 2022-12-28 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni d'apolipoprotéine c3 (apoc3) et leurs méthodes d'utilisation |
| IL296109A (en) | 2020-03-06 | 2022-11-01 | Alnylam Pharmaceuticals Inc | Ketohexokinase (khk) IRNA compositions and methods of using them |
| EP4118207A1 (fr) | 2020-03-11 | 2023-01-18 | Omega Therapeutics, Inc. | Compositions et procédés de modulation de l'expression génique de forkhead box p3 (foxp3) |
| EP4121534A1 (fr) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes pour traiter des sujets ayant un variant de gène d'alanine-glyoxylate aminotransférase hétérozygote (agxt) |
| CN116209759A (zh) | 2020-03-26 | 2023-06-02 | 阿尔尼拉姆医药品有限公司 | 冠状病毒iRNA组合物及其使用方法 |
| EP4127171A2 (fr) | 2020-03-30 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés de silençage de l'expression du gène dnajc15 |
| WO2021207167A1 (fr) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes pour le silençage de l'expression de myoc |
| WO2021206917A1 (fr) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions arni d'enzyme de conversion de l'angiotensine 2 (eca2) et procédés d'utilisation associés |
| BR112022020227A2 (pt) | 2020-04-07 | 2022-11-22 | Alnylam Pharmaceuticals Inc | Composições e métodos para silenciamento da expressão de scn9a |
| WO2021206922A1 (fr) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la serine protease 2 transmembranaire (tmprss2) et leurs procédés d'utilisation |
| CN115955972A (zh) | 2020-04-27 | 2023-04-11 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白E(APOE)iRNA剂组合物及其使用方法 |
| AU2021265813A1 (en) | 2020-04-30 | 2022-11-10 | Alnylam Pharmaceuticals, Inc. | Complement factor B (CFB) iRNA compositions and methods of use thereof |
| EP4153746A1 (fr) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression du gène marc1 |
| BR112022024420A2 (pt) | 2020-06-18 | 2023-01-17 | Alnylam Pharmaceuticals Inc | Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas |
| EP4217489A1 (fr) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de dipeptidyle peptidase 4 (dpp4) et leurs procédés d'utilisation |
| TW202229552A (zh) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法 |
| US20240035029A1 (en) | 2020-10-16 | 2024-02-01 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| WO2022079222A1 (fr) | 2020-10-16 | 2022-04-21 | Sanofi | Nouvelles compositions d'arn et méthodes d'inhibition d'angptl3 |
| CA3198823A1 (fr) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methodes et compositions pour le traitement de l'hyperoxalurie primaire |
| WO2022087329A1 (fr) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la mucine 5b (muc5b) et leurs méthodes d'utilisation |
| MX2023005490A (es) | 2020-11-13 | 2023-05-23 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso. |
| TW202237150A (zh) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物 |
| WO2022125490A1 (fr) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du facteur de coagulation x (f10) et leurs méthodes d'utilisation |
| WO2022150260A1 (fr) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du composant du complément 9 (c9) et leurs méthodes d'utilisation |
| BR112023015761A2 (pt) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | Superóxido dismutase 1 (sod1) composições de irna e métodos de uso das mesmas para tratar ou prevenir doenças neurodegenerativas associadas a superóxido dismutase 1 (sod1) |
| CN117222739A (zh) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | 朊病毒蛋白(prnp)irna组合物和其使用方法 |
| KR20230150844A (ko) | 2021-02-26 | 2023-10-31 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나아제(KHK) iRNA 조성물 및 이의 사용 방법 |
| TW202302849A (zh) | 2021-03-04 | 2023-01-16 | 美商艾拉倫製藥股份有限公司 | 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其使用方法 |
| WO2022192519A1 (fr) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la glycogène synthase kinase 3 alpha (gsk3a) et leurs procédés d'utilisation |
| AR125230A1 (es) | 2021-03-29 | 2023-06-28 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO |
| WO2022212153A1 (fr) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de proline déshydrogénase 2 (prodh2) et procédés d'utilisation associés |
| IL307926A (en) | 2021-04-26 | 2023-12-01 | Alnylam Pharmaceuticals Inc | Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them |
| JP2024519293A (ja) | 2021-04-29 | 2024-05-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法 |
| JP2024522068A (ja) | 2021-05-18 | 2024-06-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法 |
| EP4347823A1 (fr) | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du gène codant pour la protéine 3 contenant un domaine phospholipase de type patatine (pnpla3) et procédés d'utilisation associés |
| TW202308663A (zh) | 2021-06-04 | 2023-03-01 | 美商艾拉倫製藥股份有限公司 | 人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法 |
| WO2022260939A2 (fr) | 2021-06-08 | 2022-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions et méthodes de traitement ou de prévention de la maladie de stargardt et/ou de troubles associés à la protéine 4 de liaison du rétinol (rbp4) |
| KR20240026203A (ko) | 2021-06-30 | 2024-02-27 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물 |
| EP4367242A2 (fr) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions et procédés de modulation de l'expression génique de la protéine 1 du récepteur frizzled secrété (sfrp1) |
| TW202333748A (zh) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物 |
| MX2024000981A (es) | 2021-07-21 | 2024-02-12 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso. |
| JP2024528701A (ja) | 2021-07-23 | 2024-07-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法 |
| WO2023009687A1 (fr) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de 3-hydroxy-3-méthylglutaryle-coa réductase (hmgcr) et leurs procédés d'utilisation |
| KR20240042004A (ko) | 2021-08-03 | 2024-04-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법 |
| WO2023014765A1 (fr) | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni et méthodes d'inactivation de l'angiotensinogène (agt) |
| EP4384617A1 (fr) | 2021-08-13 | 2024-06-19 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du facteur xii (f12) et leurs procédés d'utilisation |
| WO2023044370A2 (fr) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni et procédés de silençage de composant du complément 3 (c3) |
| CA3232420A1 (fr) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions modulatrices de la sous-unite beta e de l'inhibine (inhbe) et leurs procedes d'utilisation |
| CN118369427A (zh) | 2021-10-15 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | 肝外递送irna组合物及其使用方法 |
| WO2023076450A2 (fr) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de la huntingtine (htt) et leurs procédés d'utilisation |
| AU2022378567A1 (en) | 2021-10-29 | 2024-04-11 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2023141314A2 (fr) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni d'enzyme de voie de biosynthèse de sulfate d'héparine et leurs méthodes d'utilisation |
| WO2024059165A1 (fr) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436141A (en) * | 1989-02-24 | 1995-07-25 | University Of Medicine And Dentistry Of New Jersey | Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products |
| US5434070A (en) * | 1989-02-24 | 1995-07-18 | The University Of Medicine And Dentistry Of New Jersey | Reverse transcriptases from Escherichia coli and Myxococcus xanthus |
| AU672689B2 (en) * | 1991-08-30 | 1996-10-10 | University Of Medicine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
| CA2073630C (fr) * | 1991-08-30 | 2007-12-11 | Atsushi Ohshima | Methode de synthese de l'adn simple brin "stem-loop", les produits obtenus et leur utilisation |
| WO1994001550A1 (fr) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Oligonucleotides auto-stabilises utiles comme agents therapeutiques |
| JPH08506011A (ja) * | 1992-12-09 | 1996-07-02 | イー． ミラー，ジェフリー | ｃＤＮＡ合成のための方法及び組成物 |
| FR2703053B1 (fr) * | 1993-03-26 | 1995-06-16 | Genset Sa | Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications . |
| WO1995035369A1 (fr) * | 1994-06-22 | 1995-12-28 | Miller Jeffrey E | Procedes et compositions permettant la synthese d'adn complementaire |
-
1999
- 1999-10-12 JP JP2000576004A patent/JP2002527061A/ja active Pending
- 1999-10-12 EP EP99951989A patent/EP1117776A1/fr not_active Withdrawn
- 1999-10-12 BR BR9914772-6A patent/BR9914772A/pt not_active IP Right Cessation
- 1999-10-12 CA CA002346155A patent/CA2346155A1/fr not_active Abandoned
- 1999-10-12 AU AU64305/99A patent/AU6430599A/en not_active Abandoned
- 1999-10-12 IL IL14249099A patent/IL142490A0/xx unknown
- 1999-10-12 KR KR1020017004474A patent/KR20010099682A/ko not_active Application Discontinuation
- 1999-10-12 MX MXPA01003642A patent/MXPA01003642A/es unknown
- 1999-10-12 WO PCT/US1999/023933 patent/WO2000022113A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000022113A1 (fr) | 2000-04-20 |
| BR9914772A (pt) | 2001-12-11 |
| JP2002527061A (ja) | 2002-08-27 |
| CA2346155A1 (fr) | 2000-04-20 |
| MXPA01003642A (es) | 2003-07-21 |
| WO2000022113A9 (fr) | 2000-08-24 |
| KR20010099682A (ko) | 2001-11-09 |
| EP1117776A1 (fr) | 2001-07-25 |
| IL142490A0 (en) | 2002-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6430599A (en) | Enzymatic synthesis of ssdna | |
| KR20110128345A (ko) | 생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법 | |
| Feng et al. | A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi | |
| WO2000022114A9 (fr) | PRODUCTION D'ADN SIMPLE BRIN $i(IN VIVO) | |
| KR19980701418A (ko) | 안정화된 외부 가이드 서열 | |
| EP1716164A1 (fr) | Diffusion ciblee de molecule d'interference arn pour le traitement de troubles facilites par ige | |
| JP2012080889A (ja) | 多コンパートメント真核生物発現系 | |
| KR20140123054A (ko) | 생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법 | |
| WO2007084954A2 (fr) | Inhibition sélective des variantes d'épissure de l'ig20 pour traiter le cancer | |
| CN116113697A (zh) | 用于治疗癫痫的方法和组合物 | |
| US20120301449A1 (en) | Rna interference target for treating aids | |
| US20100055783A1 (en) | Nucleic acid compounds for inhibiting ras gene expression and uses thereof | |
| KR20010042848A (ko) | 인슐린유사 성장인자 ⅱ의 안티센스 올리고뉴클레오타이드서열 및 이를 이용한 세포성장 조절방법 | |
| CA2495556A1 (fr) | Procedes et kits pour la synthese de cassettes d'expression d'arnsi | |
| KR20020059608A (ko) | 생체내에서 생성된 ｓｓＤＮＡ를 이용한 유전자 발현의 변화 | |
| WO2006091112A1 (fr) | Compositions pour l’administration de molécules d’interférence arn et leur procédés d’utilisation | |
| US20030082800A1 (en) | In vivo ssDNA expression vectors for altering gene expression | |
| EP1119615B1 (fr) | Production d'adn simple brin a l'interieur d'une cellule | |
| AU2004205192B2 (en) | Production of ssDNA in vivo | |
| JP7153033B2 (ja) | 真核生物におけるｒｎａ分子の細胞型特異的な翻訳に関する系及び方法 | |
| EP1546169A2 (fr) | Ribozyme en epingle a cheveux triplex | |
| US20070160581A1 (en) | Production of ssDNA in vivo | |
| US20050260588A1 (en) | In vivo ssdna expression vectors for altering gene expression | |
| AU2003265907A1 (en) | In vivo ssdna expression vectors for altering gene expression | |
| EP1111057A1 (fr) | Ribozyme promedicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |